India’s anti-obesity drug market quadruples in five years on lifestyle disease surge
India’s anti-obesity drug market has grown more than fourfold in the last five years fuelled by rising instances of lifestyle diseases along with greater affordability and willingness among a section…
Novo Nordisk to phase out country’s largest insulin brand
In a move which could shake up the diabetes market, Novo Nordisk is discontinuing the country’s largest selling insulin, Human Mixtard, among other older insulin brands in India. Human Mixtard…
Novo Nordisk regains membership in UK pharma body
London: Danish pharmaceutical giant Novo Nordisk has regained its membership in the UK’s pharmaceutical industry body after serving a two-year suspension for breaching a national drugmakers practice code. The Association of the British…
